The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help. The interviews webpage also uses YouTube, where subtitles and translations are generated automatically by AI; please be advised to exercise caution when precise interpretation is required. For further support with YouTube, visit YouTube Help.
What’s new in immunotherapy for acute myeloid leukemia?
Naval Daver
December 15, 2020
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, Know AML spoke to Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, What’s new in immunotherapy for acute myeloid leukemia? Daver gives an overview of the immunotherapies that have been approved or are in development for acute myeloid leukemia.
To what extent do you agree with the following statements?
Please rate between 1 and 5, with 1 being 'strongly disagree' and 5 being 'strongly agree'.
